Cargando…
Responders to low-dose ATG induce CD4(+) T cell exhaustion in type 1 diabetes
BACKGROUND: Low-dose anti–thymocyte globulin (ATG) transiently preserves C-peptide and lowers HbA1c in individuals with recent-onset type 1 diabetes (T1D); however, the mechanisms of action and features of the response remain unclear. Here, we characterized the post hoc immunological outcomes of ATG...
Autores principales: | Jacobsen, Laura M., Diggins, Kirsten, Blanchfield, Lori, McNichols, James, Perry, Daniel J., Brant, Jason, Dong, Xiaoru, Bacher, Rhonda, Gersuk, Vivian H., Schatz, Desmond A., Atkinson, Mark A., Mathews, Clayton E., Haller, Michael J., Long, S. Alice, Linsley, Peter S., Brusko, Todd M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543726/ https://www.ncbi.nlm.nih.gov/pubmed/37432736 http://dx.doi.org/10.1172/jci.insight.161812 |
Ejemplares similares
-
Human immune phenotyping reveals accelerated aging in type 1 diabetes
por: Shapiro, Melanie R., et al.
Publicado: (2023) -
2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes
por: Lin, Andrea, et al.
Publicado: (2018) -
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes
por: Jacobsen, Laura M., et al.
Publicado: (2020) -
Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes
por: Haller, Michael J., et al.
Publicado: (2016) -
Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes
por: Xue, Song, et al.
Publicado: (2015)